[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,352
  • Shares Outstanding, K 45,245
  • Annual Sales, $ 10 K
  • Annual Income, $ -32,150 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta 0.60
  • Price/Sales 16,288.20
  • Price/Cash Flow N/A
  • Price/Book 8.01

Options Overview Details

View History
  • Implied Volatility 475.09% (+150.56%)
  • Historical Volatility 63.60%
  • IV Percentile 51%
  • IV Rank 41.21%
  • IV High 1,095.90% on 12/10/25
  • IV Low 40.00% on 02/12/26
  • Expected Move (DTE 18) 0.28 (10.91%)
  • Put/Call Vol Ratio 247.50
  • Today's Volume 994
  • Volume Avg (30-Day) 484
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 1,208
  • Open Int (30-Day) 876
  • Expected Range 2.29 to 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 2
  • High Estimate $-0.19
  • Low Estimate $-0.21
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +4.60%
on 08/06/26
3.08 -15.10%
on 08/04/26
-0.33 (-11.05%)
since 07/31/26
3-Month
2.50 +4.60%
on 08/06/26
3.18 -17.77%
on 07/06/26
-0.43 (-14.26%)
since 05/29/26
52-Week
2.29 +14.19%
on 03/30/26
8.53 -69.34%
on 11/05/25
-0.91 (-25.92%)
since 08/28/25

Most Recent Stories

More News
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial  of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --

GNLX : 2.62 (-1.69%)
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated...

GNLX : 2.62 (-1.69%)
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data...

GNLX : 2.62 (-1.69%)
Genelux Corporation to Participate in Upcoming Conferences

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in...

GNLX : 2.62 (-1.69%)
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.62 (-1.69%)

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 3.02
2nd Resistance Point 2.95
1st Resistance Point 2.80
Last Price 2.62
1st Support Level 2.58
2nd Support Level 2.51
3rd Support Level 2.36

See More

52-Week High 8.53
Fibonacci 61.8% 6.15
Fibonacci 50% 5.41
Fibonacci 38.2% 4.67
Last Price 2.62
52-Week Low 2.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.